Mapping pilicide anti-virulence effect in Escherichia coli, a comprehensive structure-activity study

Bioorganic and Medicinal Chemistry

Volumn 20, Issue 9, 2012, Pages 3128-3142

  Chorell, Erik ^a,b   Pinkner, Jerome S ^b   Bengtsson, Christoffer ^a   Banchelin, Thomas Sainte Luce ^a   Edvinsson, Sofie ^a   Linusson, Anna ^a   Hultgren, Scott J ^b   Almqvist, Fredrik ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 Pyridone; Antivirulence; Biofilm inhibitor; Peptidomimetic; Pilicide; Structure activity

Indexed keywords

7 (3 METHYLPHENETHYL) 5 OXO 8 PHENYL 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLIC ACID; 7 (BENZO[B]THIOPHEN 3 YLMETHYL) 8 (BENZO[D][1,3]DIOXOL 5 YL) 5 OXO 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLATE LITHIUM SALT; 7 (BENZO[B]THIOPHEN 3 YLMETHYL) 8 CYCLOPROPYL 5 OXO 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLATE LITHIUM SALT; 7 (BENZO[B]THIOPHEN 3 YLMETHYL) 8 METHOXY 5 OXO 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLATE LITHIUM SALT; 7 (BENZO[D][1,2, 3]DIAXOL 5 YLMETHYL) 5 OXO 8 (PYRIDIN 3 YL) 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLATE LITHIUM SALT; 7 (BENZO[D][1,3]DIOXOL 5 YLMETHYL) 8 (1H INDOL 3 YL) 5 OXO 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLATE LITHIUM SALT; 7 (BENZO[D][1,3]DIOXOL 5 YLMETHYL) 8 METHOXY 5 OXO 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLIC ACID; 7 (NAPHTHALEN 1 YLMETHYL) 5 OXO 8 (THIOPHEN 2 YL) 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLATE LITHIUM SALT; 7 [(1H BENZO[D][1,2, 3]TRIAXOL 1 YL)METHYL] 5 OXO 8 (PYRIDIN 3 YL) 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLATE LITHIUM SALT; 7 [(1H BENZO[D][1,2,3]TRIAZOL 1 YL)METHYL] 8 CYCLOPROPYL 5 OXO 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLATE LITHIUM SALT; 7 [(1H BENZO[D][1,2,3]TRIAZOL 1 YL)METHYL] 8 ISOPROPYL 5 OXO 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLATE LITHIUM SALT; 7 [(2,3 DIMETHYLPHENOXY)METHYL] 5 OXO 8 PHENYL 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLIC ACID; 7 [(7 METHOXY 2 OXO 2H CHROMEN 4 YL)METHYL] 5 OXO 8 (THIOPHEN 2 YL) 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLIC ACID; 7 [(7 METHOXY 2 OXO 2H CHROMEN 4 YL)METHYL] 5 OXO 8 PHENYL 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLIC ACID; 7 [(NAPHTHALEN 1 YLOXY)METHYL] 5 OXO 2 PHENYL 8 (THIOPHEN 2 YL) 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLIC ACID; 7 [(NAPHTHALEN 1 YLOXY)METHYL] 5 OXO 8 (THIOPHEN 2 YL) 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLIC ACID; 8 (1 METHYL 1H INDOL 3 YL) 7 [(NAPHTHALEN 1 YLOXY)METHYL] 5 OXO 2 M TOLYL 5H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLIC ACID; 8 (1 METHYL 1H INDOL 3 YL) 7 [(NAPHTHALEN 1 YLOXY)METHYL] 5 OXO 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLATE LITHIUM SALT; 8 (1H INDOL 3 YL) 7 (3 METHYLPHENYL) 5 OXO 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLATE LITHIUM SALT; 8 (1H INDOL 3 YL) 7 [(NAPHTHALEN 1 YLOXY)METHYL] 5 OXO 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLATE LITHIUM SALT; 8 (BENZO[D][1,3]DIOXOL 5 YL) 7 [(2,3 DIMETHYLPHENOXY)METHYL] 5 OXO 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLIC ACID; 8 (BENZO[D][1,3]DIOXOL 5 YL) 7 [(NAPHTHALEN 1 YLOXY)METHYL] 5 OXO 2M TOLYL 5H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLIC ACID; 8 (BENZO[D][1,3]DIOXOL 5 YL) 7 [(NAPHTHALEN 1 YLOXY)METHYL] 5 OXO 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLATE LITHIUM SALT; 8 CYCLOPROPYL 7 [(7 METHOXY 2 OXO 2H CHROMEN 4 YL)METHYL] 5 OXO 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLIC ACID; 8 ISOPROPYL 7 (3 METHYLPHENETHYL) 5 OXO 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLIC ACID; 8 ISOPROPYL 7 (NAPHTHALEN 1 YLMETHYL) 5 OXO 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLATE LITHIUM SALT; 8 METHOXY 7 (NAPHTHALEN 1 YLMETHYL) 5 OXO 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLATE LITHIUM SALT; ANTIINFECTIVE AGENT; PILICIDE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL VIRULENCE; BIOFILM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ESCHERICHIA COLI; LIPOPHILICITY; MEDIAN EFFECTIVE CONCENTRATION; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BIOFILMS; DISCRIMINANT ANALYSIS; ESCHERICHIA COLI; FIMBRIAE, BACTERIAL; PYRIDONES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 84859910482     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2012.01.048     Document Type: Article

References (38)

1. H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, L.B. Rice, M. Scheld, B. Spellberg, and J. Bartlett Clin. Infect. Dis. 48 2009 1
2. T.J. Wiles, R.R. Kulesus, and M.A. Mulvey Exp. Mol. Pathol. 85 2008 11
3. G.G. Anderson, J.J. Palermo, J.D. Schilling, R. Roth, J. Heuser, and S.J. Hultgren Science 301 2003 105
4. M.A. Mulvey, Y.S. Lopez-Boado, C.L. Wilson, R. Roth, W.C. Parks, J. Heuser, and S.J. Hultgren Science 282 1998 1494
5. M.A. Mulvey, J.D. Schilling, and S.J. Hultgren Infect. Immun. 69 2001 4572
6. J.D. Schilling, R.G. Lorenz, and S.J. Hultgren Infect. Immun. 70 2002 7042
7. B.S. Norinder, B. Köves, M. Yadav, A. Brauner, and C. Svanborg Microb. Pathog. 52 2012 10
8. J.A. Snyder, A.L. Lloyd, C.V. Lockatell, D.E. Johnson, and H.L.T. Mobley Infect. Immun. 74 2006 1387
9. J.W. Costerton, P.S. Stewart, and E.P. Greenberg Science 284 1999 1318
10. D. Davies Nat. Rev. Drug Disc. 2 2003 114
11. K.D. Xu, G.A. McFeters, and P.S. Stewart Microbiology UK 146 2000 547
12. M.S. Litwin, C.S. Saigal, E.M. Yano, C. Avila, S.A. Geschwind, J.M. Hanley, G.F. Joyce, R. Madison, J. Pace, S.M. Polich, and M. Wang J. Urol. 173 2005 933
13. L.A. Pratt, and R. Kolter Mol. Microbiol. 30 1998 285
14. L. Cegelski, J.S. Pinkner, N.D. Hammer, C.K. Cusumano, C.S. Hung, E. Chorell, V. Aberg, J.N. Walker, P.C. Seed, F. Almqvist, M.R. Chapman, and S.J. Hultgren Nat. Chem. Biol. 5 2009 913
15. V. Aberg, and F. Almqvist Org. Biomol. Chem. 5 2007 1827
16. E. Chorell, J.S. Pinkner, G. Phan, S. Edvinsson, F. Buelens, H. Remaut, G. Waksman, S.J. Hultgren, and F. Almqvist J. Med. Chem. 53 2010 5690
17. J.S. Pinkner, H. Remaut, F. Buelens, E. Miller, V. berg, N. Pemberton, M. Hedenström, A. Larsson, P. Seed, G. Waksman, S.J. Hultgren, and F. Almqvist Proc. Natl. Acad. Sci. U.S.A. 103 2006 17897
18. S.P. Nuccio, and A.J. Baumler Microbiol. Mol. Biol. Rev. 71 2007 551
19. E. Chorell, S. Edvinsson, and F. Almqvist Tetrahedron Lett. 51 2010 2461
20. H. Emtenäs, L. Alderin, and F. Almqvist J. Org. Chem. 66 2001 6756
21. V. Aberg, M. Sellstedt, M. Hedenstrom, J.S. Pinkner, S.J. Hultgren, and F. Almqvist Bioorg. Med. Chem. 14 2006 7563
22. E. Chorell, P. Das, and F. Almqvist J. Org. Chem. 72 2007 4917
23. N. Pemberton, V. Aberg, T. Almstedt, A. Westermark, and F. Almqvist J. Org. Chem. 69 2004 7830
24. N. Pemberton, J.S. Pinkner, J.M. Jones, L. Jakobsson, S.J. Hultgren, and F. Almqvist Tetrahedron Lett. 48 2007 4543
25. S. Wold, K. Esbensen, and P. Geladi Chemom. Intell. Lab. Syst. 2 1987 37
26. L. Eriksson, E. Johansson, N. Kettaneh-Wold, C. Wikstrom, and S. Wold Design of Experiments, Principles and Applications 2000 Umetrics Academy
27. R.C. St. John, and N.R. Draper Technometrics 17 1975 15
28. A. Linusson, M. Elofsson, I.E. Andersson, and M.K. Dahlgren Curr. Med. Chem. 17 2001
29. G.A. O'Toole, and R. Kolter Mol. Microbiol. 28 1998 449
30. M. Bylesjo, M. Rantalainen, O. Cloarec, J.K. Nicholson, E. Holmes, and J. Trygg J. Chemometr. 20 2006 341
31. S. Wold, A. Ruhe, H. Wold, and W.J. Dunn SIAM J. Sci. Stat. Comp. 5 1984 735
32. S. Wold, M. Sjostrom, and L. Eriksson Chemom. Intell. Lab. Syst. 58 2001 109
33. V. Aberg, P. Das, E. Chorell, M. Hedenstrom, J.S. Pinkner, S.J. Hultgren, and F. Almqvist Bioorg. Med. Chem. Lett. 18 2008 3536
34. V. Aberg, M. Hedenstrom, J.S. Pinkner, S.J. Hultgren, and F. Almqvist Org. Biomol. Chem. 3 2005 3886
35. ChemACX2002, CamebridgeSoft; Cambridge, MA, 2002.
36. MOE; Chemical Computing Group Inc.: Montreal, Quebec, Cananda, 2004.
37. SIMCA-P+, 12.0; Umetrics AB: Box 7960, Ume, Sweden, 2008.
38. MODDE, 7.0; Umetrics AB: Box 7960, Ume, Sweden.